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OBJECTIVES: The objectives of this study were to describe the characteristics of 
patients who were hospitalized for lung cancer in West Virginia during the year 2007 
and to identify predictors of in-hospital mortality. METHODS: Study data are drawn 
from 2007 hospital discharge records in the state of West Virginia, using the Agency 
for Health Research and Quality Healthcare Cost and Utilization Project State Inpa-
tient Database (HCUP-SID). All patients who had a primary diagnosis of lung cancer 
were included in the study. Univariate and multivariate logistic regression analyses 
were used to identify patient characteristics that were associated with in-hospital 
mortality. RESULTS: In total, 1326 discharge records with lung cancer as primary 
diagnosis were identiﬁed. The average age of patients was 66 years, the mean length 
of stay in the hospital was 8 days, and the in-hospital mortality rate was 13%. Patients 
who had comorbid conditions and complications and patients who were grouped 
under the self-pay/no charge/ others category had greater odds of in-hospital mortality 
compared with patients who were covered by private insurance (P < 0.05). CONCLU-
SIONS: Patients with comorbid conditions and complications and patients without 
adequate insurance coverage had greater odds of in-hospital mortality. One reason 
for this may be inadequate access to care because of the absence of insurance or 
underinsurance. Further studies controlling for disease stage will be required to deter-
mine whether insurance status and patient-related factors can inﬂuence outcomes from 
lung cancer in individual patients independent of their disease stage.
PCN138
THE FINANCIAL EFFECT OF THE INTRODUCTION OF PERFORMANCE-
VOLUME LIMIT (PVL) ON THE HUNGARIAN ONCOLOGY CARE
Boncz I1, Donka-Verebes É2, Oberfrank F3
1University of Pécs, Pécs, Hungary, 2Intergra Consulting Ltd., Budapest, Hungary, 3Institute of 
Experimental Medicine, Budapest, Hungary
OBJECTIVES: Hungary was the ﬁrst country in Europe fully implementing a DRG 
(Diagnosis Related Groups) like ﬁnancing method for the whole hospital care as early 
as 1993. In 2004 in addition to the DRG like ﬁnancing technique, the so-called per-
formance volume limit (PVL) was introduced forming an artiﬁcial ﬁnancial cap for 
the activity based ﬁnancing of the Hungarian hospitals. The aim of our study is to 
analyse the effect of performance-volume limit (PVL) on the performance indicators 
of acute oncology care, with special respect to the health insurance reimbursement 
not paid to health care providers. METHODS: Data were derived from the nationwide 
administrative dataset of the National Health Insurance Fund Administration (OEP) 
covering the period 2006–2008. We analysed the effect of PVL according to medical 
specialities. We calculated the average annual reimbursement rate of DRG cost-weight 
with and without the application of PVL. The loss due to PVL was calculated both 
by monetary terms and as the % of annual revenue. RESULTS: The loss of medical 
specialities measured by monetary units (Hungarian forint, HUF) and as a percent of 
their revenues was the followingin 2008-ban: Oncology 1327 million HUF (4,7%), 
Cardiology 791 million HUF (3,0%), Gynecology and obstetrics 772 million HUF 
(3,0%), internal medicine 708 million HUF (3,3%), intensive care 661 million HUF 
(2,5%), surgery 637 million HUF (3,2%), pediatrics 614 million HUF (3,9%), trau-
matology 545 million HUF (2,5%), radiotherapy 438 million HUF (3,1%). CON-
CLUSIONS: The introduction of performance-volume limit had signiﬁcantly different 
effect on the different medical specialities. Oncology care can be cosidered as one of 
the largest loser of the application of performance-volume limit.
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OPTIMISING MARKET ACCESS FOR ONCOLOGY DRUGS IN BRAZIL  
& CHINA
Dummett H, Shankland B
Double Helix Consulting, London, UK
OBJECTIVES: Brazil & China represent two fast growing markets for oncology 
products. Market access drivers for new oncology brands are not transparent. While 
manufacturers are increasingly pursuing patient access schemes to drive market access 
in developed markets, it is unclear if these will be as applicable in these emerging 
markets. METHODS: A total of 15 payers, payer advisers & price-sensitive customers 
across both public & private sectors in Brazil & China were interviewed in late 2009 
to understand their evidence requirements for new oncology products, and their open-
ness to ﬂexible pricing agreements or patient access schemes RESULTS: The primary 
market for oncology brands in China remains the self-pay hospital market, for which 
critical market access drivers are compelling local efﬁcacy data, the perceived revenue 
opportunity for the dispensing hospital and KOL endorsement. While discounts are a 
vital market access driver at this level, at national level price-volume agreements for 
high-cost oncology brands are being considered for the ﬁrst time as a criterion for 
access to the National Reimbursement Drug List (NRDL), under a pilot negotiation 
scheme. Economic arguments, based on local data, are also becoming more important 
for reimbursement. In Brazil, public payers are most concerned with cost-effectiveness, 
while private payers consider clinical beneﬁt the most important factor in decision-
making. There are no ﬂexible pricing arrangements for oncology products in Brazil, 
but both public & private payers express interest in discounts based on the duration 
of treatment. CONCLUSIONS: Outcomes-based agreements are inappropriate for 
either the Brazilian or Chinese setting due to difﬁculty in implementation and monitor-
ing. However, price-volume deals will be considered, in Brazil in the private sector 
and in China in the public sector. Further development of public PE requirements is 
anticipated in light of recent policy guidance on NRDL revision processes & NICE 
consultancy to the Health Ministry.
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OBJECTIVES: Prices of recently launched monoclonal antibodies are relatively high 
and their accessibility differs between European countries. Bevacizumab (BVZ) was 
granted full access in Germany and France, but rejected in UK. It was subject in Italy 
to payment by performance with a 50% discount for the ﬁrst 6 weeks and free after 
11 to 15 cycles. In France BVZ is reimbursed to hospitals on top of DRG costs. 
METHODS: We reviewed how such differences might affect usage of BVZ in France, 
Germany, Italy and UK. Data on drug utilization from June 2006 to July 2009 were 
extracted from the Synovate Oncology Monitor, an ongoing database tracking pre-
scribing of anti-cancer therapies for patients within and across tumours over time. 
Total sample size varied between countries, from 7,766 to 9,463 patients within the 
year ending 2009 Q2. RESULTS: Metastatic colorectal cancer (mCRC) represents the 
ﬁrst indication for BVZ, accounting for 62% of usage in France, 56% in Germany, 
and 75% in Italy. Proportions of mCRC patients receiving BVZ were 18%, 14% and 
21% in France, Germany and Italy, over the period Jul 08-Jun 09. Utilization rates 
for other tumours (breast, renal cell, brain and non-small cell lung cancer) ranged 
from 1% to 6% in France, Germany and Italy. Over the three-year period, overall 
utilization was stable in France, increased slowly in Germany and faster in Italy. In 
the UK, BVZ was prescribed to fewer than 1% of patients for all tumours. Dosages 
used and patient proﬁles were comparable across countries. CONCLUSIONS: 
Funding on top of DRG does not appear to increase drug usage, but contributes to 
early uptake. Health technology assessment conclusions inﬂuence utilization strongly. 
Payment by performance is associated with signiﬁcant development of drug penetra-
tion. The disparity of access for cancer patients raises the issue of associated outcome 
and equity.
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OBJECTIVES: Health technology assessments (HTA) typically compare the clinical 
beneﬁts and costs of a single candidate technology with an existing standard of care. 
Recently, some have argued that HTA should adopt a disease management approach 
in order to better reﬂect clinical practice, whereby the technology may simultaneously 
compete, complement or overlap with existing technologies at multiple points in the 
clinical pathway. Thus, the purpose of our study was to compare and contrast the 
disease management and traditional approaches in an HTA case study. METHODS: 
Markov models comparing photodynamic therapy (PDT) to esophagectomy for the 
treatment of Barrett’s esophagus with high-grade dysplasia were used to evaluate 
treatment cost and effectiveness. To investigate the traditional HTA approach, 
PDT was modeled as a standalone therapy. To investigate the disease management 
approach, PDT was modeled as the primary treatment with additional, secondary 
treatments (radiofrequency ablation and/or endoscopic mucosal resection) available 
in the event of PDT failure, reﬂecting local practice. RESULTS: PDT was less expen-
sive and more effective with respect to quality-adjusted life years (QALYs) than 
esophagectomy in all models. In contrast, PDT treatment resulted in more cancer 
cases than esophagectomy in all models. When comparing the two approaches to 
HTA, modeling PDT as a standalone therapy underestimated the incremental effective-
ness of PDT compared to esophagectomy (0.7 versus 1.0 QALYs) and overestimated 
the lifetime cancer incidence (5.1% versus 4.1%) and the total cost of treatment 
($21,000 versus $17,000). CONCLUSIONS: The disease management approach is 
more intensive than traditional HTA, requiring more research, data analysis and 
complex modeling. Using a disease management approach did not alter the favour-
ability of PDT with respect to esophagectomy. However, given the 20–30% difference 
observed in incremental effectiveness and cost between the two methodologies, it is 
possible that the approach taken could ultimately inﬂuence the outcome of a more 
difﬁcult decision.
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OBJECTIVES: As part of health care reform, US policymakers are debating on 
whether or not to create a centralized comparative effectiveness research (CER) entity 
to improve the efﬁciency, quality and long-term sustainability of health care. If imple-
mented, cancer is likely to be among the recommended primary CER topics. In Europe, 
